{"component": "definition", "props": {"groups": [{"size": 8, "samples": [{"hash": "8hRlJ7gxZw4", "uri": "/contracts/8hRlJ7gxZw4#impd", "label": "License and Collaboration Agreement (Sarepta Therapeutics, Inc.)", "score": 27.8501033783, "published": true}, {"hash": "9k6zIIYU3m", "uri": "/contracts/9k6zIIYU3m#impd", "label": "License and Collaboration Agreement (Summit Therapeutics PLC)", "score": 26.2416152954, "published": true}], "snippet_links": [{"key": "investigational-medicinal-product-dossier", "type": "definition", "offset": [9, 50]}], "snippet": "means an Investigational Medicinal Product Dossier.", "hash": "e9921eb5712756270e7b25f419ac11cc", "id": 1}, {"size": 7, "samples": [{"hash": "9hfDorOqgPT", "uri": "/contracts/9hfDorOqgPT#impd", "label": "Clinical Trial Collaboration and Supply Agreement (Checkmate Pharmaceuticals, Inc.)", "score": 31.5133476257, "published": true}, {"hash": "8kml14H2Tg8", "uri": "/contracts/8kml14H2Tg8#impd", "label": "Clinical Trial Collaboration and Supply Agreement (Vaccinex, Inc.)", "score": 29.5174541473, "published": true}, {"hash": "8SDlsHg63qL", "uri": "/contracts/8SDlsHg63qL#impd", "label": "Clinical Trial Collaboration and Supply Agreement (Vaccinex, Inc.)", "score": 29.2792606354, "published": true}], "snippet_links": [{"key": "investigational-medicinal-product-dossier", "type": "definition", "offset": [9, 50]}, {"key": "by-regulatory-authorities", "type": "clause", "offset": [84, 109]}, {"key": "the-european-union", "type": "clause", "offset": [113, 131]}, {"key": "the-performance", "type": "clause", "offset": [136, 151]}, {"key": "clinical-trials", "type": "definition", "offset": [155, 170]}, {"key": "member-states", "type": "definition", "offset": [201, 214]}], "snippet": "means an Investigational Medicinal Product Dossier which includes all data required by Regulatory Authorities in the European Union for the performance of clinical trials in one or more European Union member states.", "hash": "3be912e6f9af24d59504415184e23c61", "id": 2}, {"size": 6, "samples": [{"hash": "60GapYxi4tt", "uri": "/contracts/60GapYxi4tt#impd", "label": "Toll Manufacturing and Service Agreement (Bluebird Bio, Inc.)", "score": 28.5797405243, "published": true}, {"hash": "kG4tngN2kTy", "uri": "/contracts/kG4tngN2kTy#impd", "label": "Toll Manufacturing and Service Agreement (Bluebird Bio, Inc.)", "score": 28.1389465332, "published": true}, {"hash": "bgYoMaBp4e4", "uri": "/contracts/bgYoMaBp4e4#impd", "label": "Partnership Agreement (Minerva Neurosciences, Inc.)", "score": 23.2683086395, "published": true}], "snippet_links": [{"key": "investigational-medicinal-product-dossier", "type": "definition", "offset": [6, 47]}], "snippet": "means Investigational Medicinal Product Dossier.", "hash": "1a837a9dd01feb247536f2ebcbf9ab5d", "id": 3}, {"size": 3, "samples": [{"hash": "5ou1dIhTIka", "uri": "/contracts/5ou1dIhTIka#impd", "label": "Development and Commercialisation Agreement (Dermira, Inc.)", "score": 24.7419567108, "published": true}, {"hash": "ar6a4fJS3B5", "uri": "/contracts/ar6a4fJS3B5#impd", "label": "Development and Commercialisation Agreement (Dermira, Inc.)", "score": 24.6516094208, "published": true}, {"hash": "6oqgKbqaG1H", "uri": "/contracts/6oqgKbqaG1H#impd", "label": "Development and Commercialisation Agreement (Dermira, Inc.)", "score": 24.4818611145, "published": true}], "snippet_links": [{"key": "the-documentation-accompanying", "type": "clause", "offset": [6, 36]}, {"key": "in-relation-to", "type": "clause", "offset": [67, 81]}, {"key": "control-of-the", "type": "clause", "offset": [111, 125]}, {"key": "investigational-medicinal-product", "type": "definition", "offset": [126, 159]}, {"key": "clinical-studies", "type": "clause", "offset": [179, 195]}, {"key": "clinical-use", "type": "definition", "offset": [209, 221]}], "snippet": "means the documentation accompanying a CTA, comprising information in relation to the quality, manufacture and control of the investigational medicinal product, and data from non-clinical studies and from its clinical use.", "hash": "6cad14cc8fab260f527452c2300bfd6e", "id": 4}, {"size": 3, "samples": [{"hash": "5I8PKnn9IsB", "uri": "/contracts/5I8PKnn9IsB#impd", "label": "License Agreement (Kite Pharma, Inc.)", "score": 25.4572219849, "published": true}, {"hash": "fz2KJ23a6uA", "uri": "/contracts/fz2KJ23a6uA#impd", "label": "License Agreement (Kite Pharma, Inc.)", "score": 25.377822876, "published": true}, {"hash": "ifAlPgPlak3", "uri": "/contracts/ifAlPgPlak3#impd", "label": "License Agreement (Kite Pharma, Inc.)", "score": 25.2546195984, "published": true}], "snippet_links": [{"key": "investigational-medicinal-product-dossier", "type": "definition", "offset": [9, 50]}, {"key": "clinical-testing", "type": "clause", "offset": [93, 109]}, {"key": "licensed-product", "type": "definition", "offset": [115, 131]}, {"key": "in-the-field", "type": "clause", "offset": [140, 152]}], "snippet": "means an Investigational Medicinal Product Dossier, or similar application to commence human clinical testing of a Licensed Product for use in the Field submitted to the EMEA, or its equivalent.", "hash": "dbe64395fe92d7a49640734faf5f6e72", "id": 5}, {"size": 2, "samples": [{"hash": "fKY0eMypDbY", "uri": "/contracts/fKY0eMypDbY#impd", "label": "License and Collaboration Agreement (Signal Genetics, Inc.)", "score": 28.0088977814, "published": true}, {"hash": "gWmXIC8lnDF", "uri": "/contracts/gWmXIC8lnDF#impd", "label": "License and Collaboration Agreement (Signal Genetics, Inc.)", "score": 27.918548584, "published": true}], "snippet_links": [{"key": "investigational-medicinal-product-dossier", "type": "definition", "offset": [9, 50]}, {"key": "data-package", "type": "clause", "offset": [87, 99]}, {"key": "regulatory-authority", "type": "clause", "offset": [120, 140]}], "snippet": "means an Investigational Medicinal Product Dossier, any successor thereto or any other data package for submission to a Regulatory Authority as part of a CTA.", "hash": "3d16bbf78a168fc84af955110d910bf0", "id": 6}, {"size": 2, "samples": [{"hash": "gVMLIdOwLMN", "uri": "/contracts/gVMLIdOwLMN#impd", "label": "Option and License Agreement (Quark Pharmaceuticals Inc)", "score": 21.8952770233, "published": true}, {"hash": "8GQQOcvE3fG", "uri": "/contracts/8GQQOcvE3fG#impd", "label": "Option and License Agreement (Quark Biotech Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "product-development", "type": "definition", "offset": [33, 52]}], "snippet": "means an Investigational Medical Product Development filed with the EMEA in Europe.", "hash": "0a84171dfc703fdb254faa44e1e561fd", "id": 7}, {"size": 2, "samples": [{"hash": "51IMvLCuiHz", "uri": "/contracts/51IMvLCuiHz#impd", "label": "Clinical Trial and Option Agreement (Vaccitech PLC)", "score": 32.2689933777, "published": true}, {"hash": "hHORzcWzWH7", "uri": "/contracts/hHORzcWzWH7#impd", "label": "Clinical Trial and Option Agreement (Vaccitech LTD)", "score": 32.1868591309, "published": true}], "snippet_links": [{"key": "in-clause", "type": "clause", "offset": [22, 31]}], "snippet": "has the meaning given in clause 2.5;", "hash": "2f2a8226ca37ff5c34289984d8bb2805", "id": 8}, {"size": 2, "samples": [{"hash": "jbeRDhjKqag", "uri": "/contracts/jbeRDhjKqag#impd", "label": "Collaboration Agreement", "score": 31.3408622742, "published": true}, {"hash": "3n3jPuzp7nO", "uri": "/contracts/3n3jPuzp7nO#impd", "label": "Collaboration Agreement (Coronado Biosciences Inc)", "score": 23.2231349945, "published": true}], "snippet_links": [{"key": "investigational-medicinal-product-dossier", "type": "definition", "offset": [10, 51]}, {"key": "medical-devices", "type": "definition", "offset": [114, 129]}, {"key": "the-application", "type": "clause", "offset": [145, 160]}, {"key": "the-authorization", "type": "clause", "offset": [165, 182]}, {"key": "the-\u2587", "type": "clause", "offset": [186, 191]}, {"key": "phase-ii-trial", "type": "definition", "offset": [195, 209]}, {"key": "supplements-and-amendments", "type": "clause", "offset": [274, 300]}], "snippet": "means the Investigational Medicinal Product Dossier filed by \u2587\u2587\u2587\u2587 with the German Federal Institute for Drugs and Medical Devices, together with the application for the authorization of the \u2587\u2587\u2587\u2587 Phase II Trial, reports mentioned therein and updates of such reports, and all supplements and amendments thereto.", "hash": "89ef4bc2ae4d584add2412100f92f675", "id": 9}, {"size": 2, "samples": [{"hash": "dHs20GeQUNY", "uri": "/contracts/dHs20GeQUNY#impd", "label": "License and Collaboration Agreement (Nymox Pharmaceutical Corp)", "score": 22.4182071686, "published": true}], "snippet_links": [{"key": "investigational-medicinal-product-dossier", "type": "definition", "offset": [6, 47]}, {"key": "the-product", "type": "clause", "offset": [52, 63]}, {"key": "form-of", "type": "definition", "offset": [97, 104]}, {"key": "according-to", "type": "definition", "offset": [136, 148]}, {"key": "in-particular", "type": "clause", "offset": [181, 194]}, {"key": "annex-13", "type": "definition", "offset": [198, 206]}], "snippet": "means Investigational Medicinal Product Dossier for the Product and the Compound (whether in the form of API or otherwise) manufactured according to Volume 4 of cGMP Guidelines and in particular to Annex 13 of such Guidelines.", "hash": "708bd5b204ad5bde452761a23253cbb2", "id": 10}], "next_curs": "ClESS2oVc35sYXdpbnNpZGVyY29udHJhY3Rzci0LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiINaW1wZCMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"size": 40, "title": "IMPD", "snippet": "means an Investigational Medicinal Product Dossier.", "id": "impd", "examples": ["If for any reason IPMD and the Investors do not hold the Expert Selection Meeting within fifteen business days of the Objection Consideration Date or are unable to agree on an Expert at the Expert Selection Meeting by the end of such period (the \u201cExpert Consideration Period\u201d), then the Investors, on the one hand, and IPMD, on the other hand, shall promptly select in good faith, by written notice to the other, an Expert that is independent from each of <strong>IMPD</strong> and Investors (each, a \u201cSelected Expert\u201d).", "In the event of an Objection Notice, <strong>IMPD</strong> shall have five business days to determine whether or not it agrees with any of the objections and the proposed changes set forth therein.", "If, on or before the last business day such five business day period (the \u201cObjection Consideration Date\u201d), <strong>IMPD</strong> agrees with the Investors\u2019 proposed changes in the Objection Notice, then the Consolidation Transaction Notice shall be modified accordingly to reflect such changes.", "Each of the Selected Experts that are selected by <strong>IMPD</strong> and the Investors shall meet promptly (and in no event later than ten business days following the end of the Expert Consideration Period) in person or by teleconference and select a single nationally or regionally recognized investment bank that is independent from each of IPMD and the Investors to serve as the Expert.", "HEMISPHERX is responsible for assuring changes are in accordance with and/or reported to the investigational, marketing and/or any other filing with regulatory agencies (IND, <strong>IMPD</strong>, CTA, NDA, MA, etc.) and for informing SCIEN of any changes requested by regulatory agencies.", "The Charity may amend any draft <strong>IMPD</strong> prepared by the Company before it is submitted to the relevant Regulatory Authority provided that where the Charity amends the section of the draft <strong>IMPD</strong> dealing with GMP Agent Material, the Company shall have the opportunity to review and comment on any such amendment and the Parties shall use reasonable endeavours to agree a mutually acceptable draft <strong>IMPD</strong> in good faith before it is submitted to the relevant Regulatory Authority.", "The Charity will provide to the Company copies of the <strong>IMPD</strong> and IB within [***] of their finalisation.", "N/A \u00b7 Maintain the Specifications file for Product \u00b7 Notify Micromet of any changes to the Specifications file; \u00b7 Assurance of consistency of current Specifications file and <strong>IMPD</strong>/ IND versions and notify Micromet.", "If the Company is supplying GMP Agent Material then, at the Charity\u2019s request, the Company will prepare and provide to the Charity a first draft of the <strong>IMPD</strong> within [***] by the Charity.", "Documents like the protocol, the IB, and <strong>IMPD</strong> are assessed jointly by one participating member state and the other concerned member states of a VHP."], "related": [["mfda", "MFDA", "MFDA"], ["pmda", "PMDA", "PMDA"], ["bla", "BLA", "BLA"], ["cfda", "CFDA", "CFDA"], ["mhlw", "MHLW", "MHLW"]], "related_snippets": [], "updated": "2026-04-15T04:23:14+00:00"}, "json": true, "cursor": ""}}